Pathway of Innovation from Research to Patients Conference

Published: 9-Apr-2015

11 June 2015

Conference

Wellcome Trust, London, UK


This one-day regulatory conference will showcase the collaborative approach between stakeholders to support innovation and to facilitate clinical development and timely access to new treatments and vaccines.

Experts and speakers from the MHRA and the National Institute for Biological Standards and Control (NIBSC), the life science industry, the Wellcome Trust, the Jenner Institute and patient organisations will highlight the latest thinking on topics including: patient involvement in regulatory decision-making and drug development; NIBSC MHRA post-merger: this session is focusing on advanced therapy medicinal products and biosimilars; accelerated regulatory approvals and processes – case study: Response against the Ebola Virus Disease from bench science to clinical research, lessons learned and applicability to other therapeutic areas.

Organisers: UK Bioindustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA)

www.biamhraconference.org/?dm_i=1TUV,3AZ75,E91DH4,BTRQN,1

Trending Articles

  1. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  2. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany
  3. Making Pharmaceuticals 23–24 April 2024 | Exhibition | Coventry, UK
  4. Interphex 16-18 April 2024 | Conference and Exhibition | New York, US
  5. CPhI North America 7-9 May 2024 | Exhibition | Pennsylvania, US

You may also like

Regulatory

BIA responds to NICE methods and processes review

Going forward, the BIA will continue to work with NICE as it implements these changes to its manual
Research & Development

The power of national collaboration

To expedite the scale-up and production of a COVID-19 vaccine, the UK BioIndustry Association issued a call to arms to its members, reports Steve Bates, CEO
Research & Development

UK Government puts forward revised biopharma R&D tax credit cap

The UK BioIndustry Association has welcomed revised proposals to ensure genuine biotech companies are not penalised by a cap on R&D tax credits
Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Regulatory

NHS, Pharma and Biotech industries call on Government to protect patients in future UK-EU relationship

A coalition from the UK’s health sector say Brexit negotiators have a responsibility to protect 500 million patients on both sides of the Channel. The group is calling on both sides to make patients and public health central to the Political Declaration for the future relationship between the UK and the EU
Regulatory

MPs back amendment to keep UK in EU medicines regulatory network

Industry insiders comment on disruptions to the supply of medicines post-Brexit and what the MPs backed amendment means for British patients
Media

Life Sciences sector responds to report on the impact of Brexit

The Business, Energy and Indsutrial Strategy (BEIS) Committee report calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry
Subscribe now